Advertisement
News
Advertisement

OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies

Wed, 11/16/2011 - 3:33am
Bio-Medicine.Org

SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, today announced it has entered into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma with the goal of identifying biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments. Terms of the final agreement have not been released.

(Photo: http://photos.prnewswire.com/prnh/20111116/LA07868)

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The advancement of biomarkers able to display the presence of or change in a biological response such as a protein related to a specific disease has been invaluable in improving patient outcomes in the multi-billion-dollar commercial success of multiple medical therapies. Unfortunately, the discovery of biomarkers in the field of cancer immunotherapy has been elusive. Serametrix has been leading the field in developing validated tests to identify such biomarkers, providing simple and robust methods that deliver accurate and reliable results. Using Serametrix's proprietary Seromic™ Profiling Assay, samples of blood taken from patients in OncoSec's three clinical studies will be analyzed with the goal of detecting potential predictive biomarkers and provide an understanding of the broad humoral (antibody) anti-tumor response resulting from OncoSec's immune therapy using DNA IL-12 and electroporation. Identification of a new biomarker(s) may enable the optimal selection of patients most likely to respond to OncoSec's

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading